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Abstract
Background: Miscarriage is a common complication in pregnancy and there is still a lack of biomarkers usable
in asymptomatic patients before the event occurs. Periostin (PER), whose levels rise particularly during injury or
inflammation, has been shown to play an important local role in implantation and early embryonic development.
As PER has been described as a biomarker in various medical conditions we intended to evaluate if changes in PER
serum levels may help to identify women at risk for spontaneous abortion in the first trimester.
Methods: Women between 18 and 42 years without confounding comorbidities who conceived by IVF/ICSI and
ovarian hyperstimulation were analysed in the study after informed consent. Maternal serum samples from 41
patients were assessed at the time of pregnancy testing (PT) and the following first ultrasound checkup (US).
Patients were subsequently divided in two groups: (1) patients with subsequent miscarriage in the first trimester
(n = 18) and (2) patients with ongoing pregnancy (n = 23), allowing for statistical analysis and investigating the
change of PER levels per individual. PER levels were measured using enzyme-linked immunosorbent assay.
Statistical analysis was performed using the Fisher exact and Student’s t test. p ≤ 0.05 was considered to be
significant.
Results: There was no significant difference concerning possible confounders between the two groups. We did
not find any significant difference in PER levels at the time point of PT or US. By investigating the interindividual
changes of PER between the two time points however, we observed that patients with a following miscarriage
showed increasing levels of PER at the time point of PT compared to US in contrast to patients with an ongoing
pregnancy who demonstrated a decrease in PER levels. These alterations were significant in the absolute as well as
in the relative comparison.
Conclusion: The relative expression of PER between PT and US is significantly altered in asymptomatic women
with subsequent miscarriage compared to women with ongoing pregnancy. Therefore systemic PER levels might
represent a potential promising biomarker for the assessment of pregnancy outcome.
Trial registration: Not applicable.
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Background
Despite the lack of consistent definitions, miscarriage
(spontaneous abortion) is often defined as intrauterine
pregnancy demise confirmed by ultrasound before the
24th week of gestation [1]. Miscarriage is a common
complication in pregnancy and affects about 8 to 20% of
clinically recognized pregnancies in the first 20 weeks of
gestation [2]. Among others, the causes of early preg-
nancy loss are various, including cytogenetic abnormal-
ities [3] as well as placental development, advanced
maternal age [4], previous miscarriage [5], body mass
index before pregnancy less than 18.5 or above 25 kg/
m2 [6] as well as heavy maternal smoking [7].
As the fetus represents a semi-allograft, immune
mechanisms are discussed as contributing factors.
Periostin (PER) is a 90 kDa extracellular protein which
is expressed in multiple compartments of the body, es-
pecially in aorta, stomach, lower gastrointestinal tract,
placenta and uterus [8]. Recent studies have been pub-
lished evaluating its role in skin, bone, kidney, heart,
lung, blood vessel, and allergic reactions, as well as can-
cer [8–10]. Levels rise particularly during injury or in-
flammation reactions. Furthermore, PER is a ligand for
ανβ3- and ανβ 5-integrins, proteins relevant in implant-
ation [11], and promotes cell motility [12, 13]. Its
expression is triggered by transforming growth factor
(TGF)-b, IL-4, and IL-13 [14, 15].
Of note many mechanisms of embryo implantation
have first been described in cancer and metastasis. In
oncology PER plays a crucial role especially in metastasis
where it has been shown to increase Wnt signaling, a
pathway that is also involved in embryo implantation
[16] and in cancer stem cells [17, 18].
PER seems to be essential for metastatic cell mainten-
ance and blocking PER results in metastasis prevention
[19]. Another possible pathway of PER in facilitating
metastasis is the formation of the immunosuppressive
premetastatic niche formation [20].
In order to evaluate the regulation of PER during early
pregnancy Anh et al. showed that periostin gene expres-
sion in the bovine endometrium is triggered by proges-
terone, while interferon tau seems to lower local PER
levels [21]. On the other hand, Hiroi et al. describe that
PER-levels are increased during the proliferative phase
and decrease in the second half of menstrual cycle [22].
In addition, PER plays an important role in embryo
development as it was shown to be present at amniotic
membranes and to be higher expressed in neonatal
umbilical cord than in adult serum [23–25]. Further-
more, an important pathway during early pregnancy,
Wnt-pathway,is targeted by PER [26].
Morelli et al. demonstrated in a case-control-study
that PER mRNA and protein levels were lower in decid-
ual and trophoblastic tissues from women with
miscarriages in late first trimester compared to women
with intact pregnancies, who underwent abortion induc-
tion. They concluded therefore that PER represents a
marker of a viable pregnancy in the first trimester [18].
However, since this analysis included patients at 12 weeks
of gestation when the miscarriage already had occurred
and tissue was examined rather than female serum, these
results do not allow prognostic conclusions for the out-
come of the pregnancy during the first trimester.
As PER has been described as a biomarker in various
medical conditions [14, 27, 28] we evaluated if changes
in PER serum levels may help identify women at risk for
spontaneous abortion in the first trimester.
Methods
After informed consent, 41 pregnant women in the
study who had undergone ovarian hyperstimulation for
in vitro fertilization with or without intracytoplasmic
sperm injection were included. Inclusion criteria were:
age between 18 and 42 years, pregnancy after ovarian
hyperstimulation followed by embryo transfer. Women
with possible confounding comorbidities (autoimmune
diseases, essential hypertonia, diabetes mellitus or the
intake of confounding medication) or a history of recur-
rent miscarriage or implantation failure were excluded.
The study was approved by the Ethical Committee of
Heidelberg University (protocol S-243/2015). Maternal
serum samples were obtained at the time of pregnancy
testing (PT) and the following first ultrasound checkup
(US) after approximately 10 days (9.9 ± 1.5 (group 1)
days vs. 10.7 ± 2.1 (group 2) days) for the measurement
of PER. Pregnancies were adequately developed with
normal HCG rise at the time of the first US. Patients
with a positive pregnancy test were subsequently divided
in two groups: (1) patients with subsequent miscarriage
in the first trimester (missed abortion, incomplete spon-
taneous abortion or complete spontaneous abortion,
n = 18) later in pregnancy and (2) patients with ongoing
pregnancy (n = 23).
ELISA assays
PER levels were analysed using the AdipoGen® Elisa kit
for Human Periostin, catalog no. AG-45B-004-KI01, Lot
K2321605, Adipogen International, Liestal, Switzerland.
Serum samples were obtained and centrifuged for 20 min,
1200 x g, 10 °C. ELISA reagent (Wash Buffer, ELISA buf-
fer, Detection Antibody, HRP labeled Streptavidin and
Human Periostin standard) preparations were performed
as described by the manufacturer.
Standard curve was prepared as described by the
manufacturer, obtaining concentrations of 5000 pg/ml,
2500 pg/ml, 1250 pg/ml, 625 pg/ml, 312 pg/ml, 156 pg/
ml, 78 pg/ml and 0 pg/ml). Samples were diluted 1/50 in
ELISA buffer, as recommended.
Freis et al. Reproductive Biology and Endocrinology  (2017) 15:87 Page 2 of 6
100 μl of different standards and 100 μl of diluted
serum were added to each well of the prepared micro-
plate in duplicates. After incubation (2 h at 37 °C), wells
were aspirated and washed. 100 μl of diluted Detection
Antibody was added to each well, followed by incubation
for 1 h at 37 °C. Again, supernatant was aspirated and
the coated wells were washed. Afterwards 100 μl of di-
luted HRP labeled Streptavidin was added. After incuba-
tion for 30 min at room temperature, supernatant was
aspirated and wells were washed, before 100 μl of TMB
substrate solution were overlayed. Color reaction was
allowed to develop in the dark for 15 min before 50 μl
of stop solution were added.
Optical density of each well was measured using a
microplate reader set to 450 nm with wave length cor-
rection of 570 nm.
Statistical analysis
Statistical analysis was performed using the Kolmogorov–
Smirnov-test, the Fisher-exact-test and unpaired Student’s
t test. A p-value ≤ 0.05 was considered to be significant.
Results
Descriptive data of patients are demonstrated in Table 1.
There was no significant difference in age (34.2 ± 4.0
(group 1) years vs. 33.0 ± 6.3 (group 2) years) or body
mass index in group 1 and 2 with 25.8 ± 5.1 kg/m2 in
group 1 vs. 24.4 ± 4.4 kg/m2 in group 2. Embryo quality
was similar in both groups. We grouped the embryos
based on “The Istanbul consensus workshop on embryo
assessment” [29] and had a transfer of poor embryos in
3 of 18 patients with miscarriage (16.7%) and in 8 of 23
patients with ongoing pregnancy (34.8%). Fishers exact-
test revealed a p-value of 0.29 (Table 2). Additionally, no
statistically significant difference in day of transfer with
3.8 ± 1.3 in group 1 vs. 4.5 ± 1.0 in group 2 (Table 2) or
in time between pregnancy test and ultrasound control
with 9.9 ± 1.5 days in group 1 vs. 10.7 ± 2.1 days in
group 2 (Table 1) was observed. All values are given in
mean ± STD.
We obtained samples from both time points in 10 of
18 patients in group 1 (55.6%) and in 17 of 23 patients
in group 2 (73.9%), allowing to investigate if there were
any temporal or relative changes between pregnancy test
and the time of the ultrasound control between the two
groups.
Absolute and relative concentrations of PER by
Kolmogorov–Smirnov-test revealed a normal distribu-
tion pattern.
We did not observe any significant difference in PER
levels at the time point of pregnancy testing or the time
point of ultrasound control (Table 3).
However, by investigating the temporal changes of
PER levels within the two groups, we observed that
Table 1 Descriptive data of patients
Nr Abortion Ongoing
pregnacy
Age BMI PT US t(US-
PT(d))
1 yes no 38 21.4 4 + 0
2 yes no 26 30.1 4 + 3
3 yes no 32 23.3 4 + 0 5 + 2 9
4 yes no 34 21.9 4 + 0
5 yes no 39 20.2 4 + 0
6 yes no 33 33.1 4 + 3 5 + 5 9
7 yes no 36 24.9 4 + 2
8 yes no 35 22.0 4 + 0
9 yes no 41 30.7 4 + 0 5 + 4 11
10 yes no 32 24.4 4 + 0 5 + 5 12
11 yes no 36 35.2 4 + 0 5 + 3 10
12 yes no 35 30.8 4 + 0 5 + 5 12
13 yes no 34 29.7 4 + 0 5 + 0 7
14 yes no 31 22.5 4 + 0
15 yes no 30 20.0 4 + 0
16 yes no 40 23.0 4 + 0 5 + 3 10
17 yes no 35 32.0 4 + 0 5 + 3 10
18 yes no 28 19.3 4 + 0 5 + 2 9
19 no yes 29 23.7 4 + 0
20 no yes 34 21.5 4 + 0 5 + 4 11
21 no yes 31 19.7 4 + 3 5 + 6 10
22 no yes 33 23.6 4 + 0 5 + 3 10
23 no yes 34 25.4 4 + 0 5 + 4 11
24 no yes 37 27.0 4 + 0
25 no yes 41 21.5 4 + 0
26 no yes 32 25.4 4 + 0 5 + 4 11
27 no yes 31 29.0 4 + 0
28 no yes 35 24.7 4 + 0
29 no yes 30 27.3 4 + 0 6 + 5 18
30 no yes 10 38.2 4 + 1 5 + 4 10
31 no yes 35 27.1 4 + 0 5 + 3 10
32 no yes 29 21.0 4 + 0 5 + 2 9
33 no yes 37 25.7 4 + 0 5 + 3 10
34 no yes 38 21.3 4 + 0 5 + 3 10
35 no yes 41 24.1 4 + 0 5 + 3 10
36 no yes 33 27.0 4 + 0 5 + 4 11
37 no yes 41 23.2 4 + 0 5 + 4 11
38 no yes 29 30.1 4 + 0
39 no yes 30 19.5 4 + 0 5+4 11
40 no yes 37 18.6 4 + 0 5 + 2 9
41 no yes 33 18.3 4 + 0 5 + 3 10
ttest ns ns ns
PT, pregnancy testing, US, ultrasound control, ns, not significant
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patients with a miscarriage showed increasing levels of
PER at the time point of PT compared to US
(+3622.5 ± 1768.47 pg/ml) in contrast to patients with
an ongoing pregnancy who showed a decrease in PER
levels (− 1750.29 ± 1461.51 pg/ml, p < 0.05) (Table 4).
Based on this observation, we built the ratio of PER
expression at the time point of first ultrasound relative
to pregnancy testing. The relative expression of PER was
significantly higher in patients with miscarriage com-
pared to control patients with ongoing pregnancy
(1.24 ± 0.12 vs. 0.97 ± 0.06, p < 0.05).
Ratio of hCG-levels between the 6. week of gestation
and the time of pregnancy testing did not differ signifi-
cantly between the two groups (53.46 ± 54.01 in patients
with miscarriage vs. 67.79 ± 54.37 in women with on-
going pregnancy, p = 0.52).
Discussion
This study is the first study, to the best of our know-
ledge, evaluating systemic levels of PER in the first
weeks of pregnancy in order to investigate the differ-
ences between women who are going to abort compared
to ongoing pregnancy.
As ultrasound cannot determine pregnancy progress,
different hormone assessments have been published in
order to help predict pregnancy outcome, such as hu-
man chorionic gonadotropin (hCG) [30, 31], progester-
one [30, 31], kisspeptin [32], activin A [33], activin B
[34], follistatin [35], CA-125 [31, 36], pregnancy associ-
ated plasma protein A (PAPP-A) [31, 37] or macrophage
inhibitory cytokine-1 [38]. However, none of these fac-
tors have been established as a biomarker in early preg-
nancy for miscarriage.
The most appropriate time point to evaluate the risk
of miscarriage would be already at the time of pregnancy
testing. However, we could not identify any significant
changes in PER expression at the time of pregnancy test-
ing. The next possible time point in routine practical use
to evaluate a possible screening biomarker for miscar-
riage is the time point of ultrasound control in the 6th
week of gestation. Again, we could not identify signifi-
cant changes between the two groups. This observation
may be due to high interindividual variations and the
small sample size, however the intraindividual variation
Table 2 Descriptive data of embryos transferred
Nr Abortion Ongoing
pregnacy
day of embryo
transfer
Embryo
quality
1 yes no day 5 4AA, 4AA
2 yes no day 4 11A
3 yes no day 4 4B, 5B
4 yes no day 5 4AB, 4AA
5 yes no day 2 4B
6 yes no day 4 Blastocyst 1, Blastocyst 2
7 yes no day 5 Blastocyst 1, Blastocyst 2
8 yes no day 2 4A, 4A
9 yes no day 2 2A
10 yes no day 5 8A, 8C
11 yes no day 2 8B, 7C
12 yes no day 5 Blastocyst 1, Blastocyst 2
13 yes no day 4 4BA, 3AA
14 yes no day 3 4AA, 4AA
15 yes no day 2 9C, 5B, 8C
16 yes no day 5 4AA, Blastocyst 2
17 yes no day 5 3AB, Blastocyst 2
18 yes no day 5 3BB
19 no yes day 4 12B
20 no yes day 5 4AA hatching
21 no yes day 2 2A, 4B
22 no yes day 2 5B
23 no yes day 5 Blastocyst 2
24 no yes day 3 9B
25 no yes day 4 Morula
26 no yes day 5 4BB, 4BB
27 no yes day 5 Blastocyst 1, Blastocyst 2
28 no yes day 5 Morula, Blastocyst 1
29 no yes day 5 Blastocyst 1
30 no yes day 5 3BA
31 no yes day 5 4AA
32 no yes day 5 Blastocyst 1
33 no yes day 4 4AB, 3AB
34 no yes day 5 Morula, Blastocyst 1
35 no yes day 5 4BA, Blastocst 1
36 no yes day 5 Blastocyst, 3BA
37 no yes day 5 Blastocyst 1
38 no yes day 4 Morula, Morula
39 no yes day 5 4AA, 4AA
40 no yes day 5 4AB, 3AB
41 no yes day 5 3BA, 4AA
ttest ns
Table 3 Results of Periostin assessment
Group I
(abortion)
Group II
(control)
n n ttest
Pregnancy
test (PT)
18 22,067.22 ±
1445.5 pg/ml
23 26,736.52 ±
2562.96 pg/ml
ns
Ultrasound
Control (US)
10 21,875.00 ±
1256.55 pg/ml
17 25,855.00 ±
2516.38 pg/ml
ns
All values are given in mean ± SEM
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seems to be low, as the sequential values show signifi-
cant changes over time. Therefore we aimed to investi-
gate if there were any intraindividual alterations in the
temporal expression to differentiate between the two
groups. The relative expression of PER over time was
significantly higher in patients with miscarriage com-
pared to control patients with ongoing pregnancy. The
fact that PER is overexpressed in different diseases char-
acterized by inflammation [8] can represent a possible
explanation for our observations. The important role of
PER in embryo invasion has been described as well as
local PER expression at 12 weeks of gestation when
miscarriage has already occurred [18, 23]. However,
none of these studies evaluated systemically serum
levels. Additionally, our study assesses PER levels in an
earlier period of gestation.
Intraindividual relative expression, which eliminates
the risk of confounding comorbidities, of PER over time
represents a new possibly independent tool in risk
assessment. However one of the limitations of our study
is its small sample size and the fact that not all participa-
tions presented themselves in the 6. week of gestation,
further minimizing our sample size, therefore our results
need further validation in larger study cohorts in order
to define a precise threshold at this very early stage in
pregnancy to develop a predictive test.
Conclusion
In conclusion, we have shown for the first time that the
relative expression of PER between 4 weeks of gestation
and control ultrasound in the 6th week of gestation is
significantly altered in asymptomatic women with subse-
quent miscarriage compared to women with ongoing
pregnancy, therefore suggesting systemic PER levels as a
potential promising biomarker for pregnancy outcome
assessment. The development of an early-screening test
to identify patients who are at risk of miscarriage in the
actual pregnancy would be useful for several reasons: a
miscarriage means an enormous distress for the patient
and a predictive test with a negative result could be used
to reassure anxious patients [31, 32, 36, 37, 39, 40]. On
the other hand, a predictive test with a positive result
can warn the patients in a very early stage of pregnancy
[39], and will prohibit unnecessary prolongation of the
current pregnancy by supplementation of high doses of
progesterone, as often done in women after ART.
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